Allison M. Bock

University of Utah — United States

Medicine · Health Sciences

16h-index1.4kcitations115works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(46), CAR-T cell therapy research(19), Chronic Lymphocytic Leukemia Research(12), Cognitive and developmental aspects of mathematical skills(10), CNS Lymphoma Diagnosis and Treatment(10)

Publications115 total

Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)
Transplantation and Cellular Therapy·2026
Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) Study
Transplantation and Cellular Therapy·2026Open Access
Improved screening for pulmonary Kaposi sarcoma in a low-resource setting
AIDS·2026
Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
Journal of Medical Economics·2025Open Access
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma
Blood·2025Open Access
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Blood·2025Open Access
Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)
Blood·2025Open Access
Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL)
Blood·2025Open Access
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
Blood·2025Open Access
Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab
Blood·2025Open Access
Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)
Blood·2025
Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers
Blood·2025Open Access
Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress
Blood·2025Open Access
Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study
Blood·2025Open Access
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study
Blood·2025Open Access
Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium
Blood·2025Open Access
Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy
Blood·2025Open Access
Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis
Blood·2025
Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States
Blood·2025Open Access
Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas
Blood·2025Open Access
page 1 of 6Next →

Frequent Co-authors

Grzegorz S. Nowakowski(16), Thomas M. Habermann(11), Matthew J. Maurer(9), James R. Cerhan(9), Thomas E. Witzig(8), Yucai Wang(6), Narendranath Epperla(6), Umar Farooq(6), Stephen M. Ansell(6), Robert Pasnak(5), Raphael Mwangi(5), Brian K. Link(5), Anne J. Novak(5), Kelly B. Cartwright(4), Katrina Lea Schmerold(4), Pallawi Torka(4), Kerstin Wenzl(4), Joseph P. Novak(4), Melissa A. Hopper(4), Abigail R. Dropik(4)